Dane Leone
Stock Analyst at Raymond James
(1.16)
# 3,774
Out of 5,045 analysts
69
Total ratings
33.96%
Success rate
-7.04%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $7.34 | +158.86% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.80 | +397.76% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $12.82 | +251.01% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $58.87 | -49.04% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $654.04 | +45.25% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.08 | +525.00% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $63.37 | -27.41% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $31.34 | +120.17% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $3.72 | +115.05% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $11.82 | +18.44% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $14.13 | +310.47% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $17.16 | +307.93% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.21 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $62.25 | +1.20% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $45.62 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.49 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $68.96 | -5.74% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $292.00 | -12.67% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.52 | +607.96% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $189.05 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $7.34
Upside: +158.86%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.80
Upside: +397.76%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $12.82
Upside: +251.01%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $58.87
Upside: -49.04%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $654.04
Upside: +45.25%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.08
Upside: +525.00%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $63.37
Upside: -27.41%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $31.34
Upside: +120.17%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $3.72
Upside: +115.05%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $11.82
Upside: +18.44%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $14.13
Upside: +310.47%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $17.16
Upside: +307.93%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.21
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $62.25
Upside: +1.20%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $45.62
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.49
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $68.96
Upside: -5.74%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $292.00
Upside: -12.67%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.52
Upside: +607.96%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $189.05
Upside: -